YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13476-13486

  Véquaud, Eloïse ^a   Séveno, Céline ^a   Loussouarn, Delphine ^a,b   Engelhart, Lucie ^a   Campone, Mario ^a,c   Juin, Philippe ^a,c   Barillé Nion, Sophie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UMR INSERM U892 CNRS 6299   (France)

Author keywords

Breast cancer; Ex vivo assay; Therapy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SEPANTRONIUM BROMIDE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NAPHTHOQUINONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST CELL; CELL CYCLE ARREST; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; EX VIVO STUDY; GENOTOXICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; FEMALE; HUMANS; IMIDAZOLES; MCF-7 CELLS; NAPHTHOQUINONES; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931032129     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3638     Document Type: Article

References (37)

1. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 1: 61-70.
2. Rauch A, Hennig D1, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH. Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta. 2014; 1845:202-220.
3. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M. YM155, a novel small-molecule Survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67: 8014-8021.
4. Trocoli A, Djavaheri-Mergny M. The complex interplay between autophagy and NF-κB signaling pathways in cancer cells. Am J Cancer Res. 2011; 1: 629-649.
5. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012; 12: 121-132.
6. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010; 40: 280-293.
7. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011; 8: 528-539.
8. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012; 12: 401-410.
9. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 1: 33-40.
10. Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria:gatekeepers of response to chemotherapy. Trends Cell Biol. 2013; 23: 612-619.
11. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 2013; 13: 455-465.
12. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 1: 49-63.
13. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139: 693-706.
14. Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res. 2007; 13: 6010-6018.
15. Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res. 2012; 14: R96.
16. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL. The "Survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012; 70: 207-212.
17. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits Survivin expression. Genes Cancer. 2010; Mar 1:283-292.
18. Giaccone G1, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter phase II trial of YM155, a smallmolecule suppressor of Survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009; 27: 4481-4476.
19. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R. A multicenter phase II evaluation of the small molecule Survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011; 29: 161-166.
20. Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget. 2014; 5: 10237-10250.
21. Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res. 2014; 16: R55.
22. Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M. YM155, a selective Survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol. 2011; 39: 569-575.
23. Wood DE, Thomas A, Devi LA, Berman Y, Beavis RC, Reed JC, Newcomb EW. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene. 1998; 17: 1069-1078.
24. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011; 11: 364-374.
25. Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy- dependent apoptosis by the Survivin suppressant YM155 in prostate cancer cells. Cancer Lett. 2011; 302: 29-36.
26. Cheng S, Chang Y, Liu C, Lee J, Chan H, Kuo C, Lin K, Tsai S, Chen S, Li C, Leung E, Kanwar J, Huang C, Chang J, Cheung C. YM155 down-regulates Survivin and XIAP, modulates autophagy, and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol. 2014; Sep 14;. Epub ahead of print.
27. González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquère S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox:autophagic vacuolization before apoptotic death. J Cell Sci. 2005; 118: 3091-3102.
28. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008; 27: 6434-351.
29. Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KV, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014; [Epub ahead of print].
30. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule Survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011; 102: 614-621.
31. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 2006; 311: 1141-1146.
32. Wu ZH, Miyamoto S. Induction of a pro-apoptotic ATMNF- kappaB pathway and its repression by ATR in response to replication stress. EMBO J. 2008; 27: 1963-1973.
33. Strozyk E, Pöppelmann B, Schwarz T, Kulms D. Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene. 2006; 25: 6239-6251.
34. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, Sasamata M. YM155, a novel Survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 2011; 22: 454-462.
35. Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N, Sasamata M. Antitumor activity of YM155, a selective small-molecule Survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res. 2011; 17: 5423-5431.
36. Tang HI, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol. 2011; 82: 1066-1072.
37. Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via Survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther. 2013; 12: 326-338.